WallStreetZenWallStreetZen

NYSE: RBOT
Vicarious Surgical Inc Stock Forecast, Predictions & Price Target

OverviewForecast
EarningsDividendOwnership

Analyst price target for RBOT

Based on 3 analysts offering 12 month price targets for Vicarious Surgical Inc.
Min Forecast
$0.40+40.85%
Avg Forecast
$0.67+134.86%
Max Forecast
$1.00+252.11%

Should I buy or sell RBOT stock?

Based on 3 analysts offering ratings for Vicarious Surgical Inc.
Hold
Strong Buy
0 analysts 0%
Buy
0 analysts 0%
Hold
3 analysts 100%
Sell
0 analysts 0%
Strong Sell
0 analysts 0%

Be the first to know when Wall Street analysts revise their RBOT stock forecasts and price targets.

RBOT stock forecasts by analyst

Analyst / FirmRatingActionPrice TargetUpside/DownsideDateAnalyst Color
lockedlocked$00.00+00.00%2024-03-05
lockedlocked$00.00+00.00%2023-12-04
lockedlocked$00.00+00.00%2023-11-14

1 of 1

Forecast return on equity

Is RBOT forecast to generate an efficient return?
Company
N/A
Industry
N/A
Market
35.5%

Forecast return on assets

Is RBOT forecast to generate an efficient return on assets?
Company
N/A
Industry
N/A

RBOT revenue forecast

What is RBOT's revenue in the next 1 years based on estimates from 1 analyst?
Avg 1 year Forecast
$35.0M

RBOT vs Medical Device Stocks

TickerPricePrice TargetUp/downsideConsensus
RBOT$0.28$0.67+134.86%Hold
IRIX$3.03N/AN/A
CTSO$0.88$1.00+13.77%Hold
MOVE$0.48N/AN/A
NSYS$17.12N/AN/A
View Top Medical Device Stocks

Vicarious Surgical Stock Forecast FAQ

Is Vicarious Surgical Stock a good buy in 2024, according to Wall Street analysts?

The consensus among 3 Wall Street analysts covering (NYSE: RBOT) stock is to Hold RBOT stock.

Out of 3 analysts, 0 (0%) are recommending RBOT as a Strong Buy, 0 (0%) are recommending RBOT as a Buy, 3 (100%) are recommending RBOT as a Hold, 0 (0%) are recommending RBOT as a Sell, and 0 (0%) are recommending RBOT as a Strong Sell.

If you're new to stock investing, here's how to buy Vicarious Surgical stock.

What is RBOT's revenue growth forecast for 2027-2027?

(NYSE: RBOT) Vicarious Surgical's forecast annual revenue growth rate of N/A is not forecast to beat the US Medical Devices industry's average forecast revenue growth rate of 8.28%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 10.16%.

Vicarious Surgical's revenue in 2024 is $0.

In 2027, RBOT is forecast to generate $6,151,308,555 in revenue, with the lowest revenue forecast at $6,151,308,555 and the highest revenue forecast at $6,151,308,555.

What is RBOT's forecast return on assets (ROA) for 2024-2027?

(NYSE: RBOT) forecast ROA is N/A, which is lower than the forecast US Medical Devices industry average of N/A.

What is RBOT's Price Target?

According to 3 Wall Street analysts that have issued a 1 year RBOT price target, the average RBOT price target is $0.67, with the highest RBOT stock price forecast at $1.00 and the lowest RBOT stock price forecast at $0.40.

On average, Wall Street analysts predict that Vicarious Surgical's share price could reach $0.67 by Mar 5, 2025. The average Vicarious Surgical stock price prediction forecasts a potential upside of 134.86% from the current RBOT share price of $0.28.

What is RBOT's forecast return on equity (ROE) for 2024-2027?

(NYSE: RBOT) forecast ROE is N/A, which is considered weak.
©2024 WallStreetZen
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsHelp GuidesContactTwitterYouTubeNewsletter
Stock Tools
Top Performing AnalystsStock ScreenerStock ForecastTrending StocksStrong Buy StocksHighest Earnings StocksBest Dividend Paying StocksStatisticsStock Market SectorsStock Market IndustriesHow to Buy Stocks Online
Stock Ideas
Buy The DipBiggest Stock Gainers TodayBiggest Stock Losers Today52 Week High Stocks52 Week Low StocksMost Active Stocks TodayMost Undervalued StocksBest Penny Stocks to Buy NowBest Stocks Under $5Best Stocks Under $10
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.